Sanofi and Regeneron Present Results from Pivotal Phase 3 Study of Sarilumab …
PARIS and TARRYTOWN, N.Y., Nov. 8, 2015 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced results from a pivotal Phase 3 study of sarilumab, an investigational, human antibody against the IL-6 receptor. The results of the study, SARIL-RA-TARGET, are being presented today at an oral session during the American College of Rheumatology (ACR) Annual Meeting in San Francisco, California. The study Read more [...]